Chromocell Therapeutics Net Income

Chromocell Therapeutics (CHRO) currently reports a net income of $-72M as of June 2026. That compares with $-9M in the prior-year period — down 691.7% year over year. That is below the sector sector average of $87M. Use the charts on this page to explore Chromocell Therapeutics's net income history and peer comparisons.

Chromocell Therapeutics's net income decreased from $-9M to $-72M — a 691.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chromocell Therapeutics's net income of $-72M is lower than the its sector sector average of $87M. That is roughly 182.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Chromocell Therapeutics reported $-72M in net income as of June 2026. That compares with $-9M in the prior-year period — down 691.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-72M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $87M. From there, open related valuation or income-statement pages for Chromocell Therapeutics, and consider following CHRO for alerts when major investors trade the stock.